MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Public ClinicalTrials.gov record NCT07362225. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The MPN PROGRESSion Registry: A Retrospective and Prospective Observational Study Collecting Patient-Reported Outcomes, Electronic Health Records, and Claims Data to Track Symptoms, Treatments, and Disease Progression in Individuals Diagnosed With Myeloproliferative Neoplasms (MPNs).
Study identification
- NCT ID
- NCT07362225
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- MPN Research Foundation
- Other
- Enrollment
- 5,000 participants
Conditions and interventions
Conditions
- Accelerated Phase MPN
- Accelerated Phase Myeloproliferative Neoplasm
- Agnogenic Myeloid Metaplasia
- Blast Phase MPN
- Blast Phase Myeloproliferative Neoplasm
- Chronic Idiopathic Myelofibrosis
- ET (Essential Thrombocythemia)
- Essential Thrombocythemia (ET)
- Idiopathic Myelofibrosis
- MDS/MPN Crossover Syndromes
- MF
- MPN
- MPN (Myeloproliferative Neoplasms)
- MPN-associated Myelofibrosis
- Myelofibrosis
- Myelofibrosis (MF)
- Myelofibrosis (PMF)
- Myelofibrosis Due to and Following Polycythemia Vera
- Myelofibrosis Transformation in Essential Thrombocythemia
- Myelofibrosis With High Molecular Risk Mutations
- Myelofibrosis, Post ET
- Myelofibrosis, Post PV
- Myelofibrosis, Primary
- Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
- Myelofibrosis，MF
- Myeloproliferative Disorder
- Myeloproliferative Disorders
- Myeloproliferative Disorders (MPD)
- Myeloproliferative Neoplasm With 10% Blasts or Higher
- Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
- Myeloproliferative Neoplasm, Not Otherwise Specified
- Myeloproliferative Neoplasm, Unclassifiable
- Myeloproliferative Neoplasms
- Myeloproliferative Neoplasms (MPNs)
- Polycythemia Vera
- Polycythemia Vera (PV)
- Post-ET MF
- Post-Essential Thrombocythemia Myelofibrosis
- Post-PV MF
- Post-Polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis (PET-MF)
- Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
- Post-polycythemia Vera Myelofibrosis (PPV-MF)
- Post-polycythemia Vera Myelofibrosis (Post-PV MF)
- Post-polycythemia Vera Myelofibrosis(Post-PV MF)
- Pre-fibrotic Myelofibrosis
- Primary Myelofibrosis (MF)
- Primary Myelofibrosis (PMF)
- Secondary Myelofibrosis
- Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)
- Secondary Myelofibrosis in Myeloproliferative Disease
- Thrombocythemia Myelofibrosis (PET-MF)
- Thrombocythemia, Essential
- Thrombocythemia, Hemorrhagic
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 25, 2025
- Primary completion
- Sep 7, 2035
- Completion
- Sep 7, 2035
- Last update posted
- Jan 22, 2026
2025 – 2035
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| MPN Research Foundation | Chicago | Illinois | 60654 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07362225, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 22, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07362225 live on ClinicalTrials.gov.